A St. Louis firm races to diagnose Alzheimer’s faster
In the world of Alzheimer’s disease research, where the setbacks have been many, the advent of blood tests has been hailed as a welcome innovation. And a St. Louis company is on the cutting edge of the field, pioneering new tests in hopes of advancing drug research and one day giving patients earlier indicators of the disease. The company has been growing its workforce and competing in the crowded field of medical firms developing faster methods of diagnosing Alzheimer’s and other types of dementia.